Auvelity for Agitation in Alzheimer’s Disease: A New FDA-Approved Treatment Option in Reno, Nevada

mental healthmental health services
Written By Danielle Parks

By: VitaNova Psychiatry & Wellness

Introduction: A Long-Awaited Breakthrough for Agitation in Alzheimer’s

Agitation and hyperarousal are among the most distressing symptoms of Alzheimer’s disease—impacting patients, caregivers, and overall quality of life.

Until recently, treatment options were limited and often relied on off-label use of antipsychotics, which carry significant risks in older adults.

Now, a novel approach is emerging: Auvelity (dextromethorphan–bupropion) is gaining attention—and has received recent FDA approval for agitation in Alzheimer’s disease—marking a major shift in treatment strategy.

What Is Auvelity (Dextromethorphan–Bupropion)?

Auvelity is a combination medication consisting of:

  • dextromethorphan → modulates glutamate and sigma-1 receptors

  • bupropion → increases dopamine and norepinephrine, and prolongs dextromethorphan activity

Originally approved for major depressive disorder, its mechanism makes it uniquely suited for targeting agitation and hyperarousal.

Why Agitation Happens in Alzheimer’s Disease

Agitation in Alzheimer’s is not just “behavioral”—it’s neurobiological.

Key contributors include:

  • Glutamate dysregulation (excitotoxicity)

  • Dopamine imbalance

  • Neuroinflammation

  • Disrupted frontal-limbic control

This leads to:

  • Restlessness

  • Aggression

  • Emotional lability

  • Hyperarousal states

Traditional treatments (like antipsychotics) blunt symptoms—but don’t address these underlying pathways effectively.

How Auvelity Targets Hyperarousal and Agitation

1. NMDA Receptor Modulation

Dextromethorphan acts on glutamate pathways, helping reduce excitotoxic signaling—similar in concept (but not identical) to memantine.

2. Sigma-1 Receptor Activation

This enhances:

  • Neuroprotection

  • Stress resilience

  • Emotional regulation

3. Dopamine & Norepinephrine Support

Through bupropion, the medication:

  • Improves behavioral control

  • Reduces irritability

  • Stabilizes mood and motivation

Net Effect:

👉 Reduced agitation
👉 Lower hyperarousal
👉 Improved behavioral stability without heavy sedation

What the Latest Research Shows (2023–2025)

Recent randomized controlled trials and extension studies demonstrate:

  • Significant reduction in agitation scores (Cohen-Mansfield Agitation Inventory)

  • Rapid onset of effect (within weeks)

  • Improved caregiver burden and patient functioning

  • Favorable tolerability compared to antipsychotics

Importantly, studies show:

  • Lower risk of oversedation

  • Less cognitive worsening compared to traditional options

This is critical in Alzheimer’s care, where preserving function is essential.

Why This FDA Approval Matters

The FDA approval of Auvelity for agitation in Alzheimer’s disease represents:

  • A move away from high-risk antipsychotics

  • A shift toward mechanism-based treatment

  • Recognition that agitation is a neurochemical—not just behavioral—issue

For patients in Reno, Nevada, this opens the door to safer, more targeted care.

Clinical Considerations

Who May Benefit:

  • Alzheimer’s patients with agitation or aggression

  • Individuals with hyperarousal, irritability, or emotional dysregulation

  • Patients who cannot tolerate antipsychotics

Monitoring Considerations:

  • Blood pressure (due to bupropion component)

  • Risk of drug interactions

  • Neuropsychiatric response

Cautions:

  • Seizure risk (bupropion-related, dose-dependent)

  • Avoid in certain populations without proper evaluation

A Shift in How We Treat Behavioral Symptoms in Dementia

We are moving toward a model that:

  • Targets underlying neurobiology

  • Preserves cognition

  • Minimizes sedation and risk

Auvelity represents a key step in that direction.

Final Thoughts: A More Precise Approach to Agitation

For patients and families in Reno, Nevada, agitation in Alzheimer’s disease is no longer limited to blunt, high-risk treatment options.

With newer therapies like Auvelity (dextromethorphan–bupropion), we can begin to:

  • Address hyperarousal at the neurochemical level

  • Improve quality of life

  • Reduce caregiver strain

Call to Action

If you or a loved one is experiencing agitation, irritability, or behavioral changes related to Alzheimer’s disease, there are now more advanced, evidence-based options available.

At VitaNova Psychiatry & Wellness, we specialize in integrating the latest psychiatric treatments with personalized care.

📩 Contact: support@vitanovapsychiatryandwellness.com
🌐 Visit: vitanovapsychiatryandwellness.com

References (APA 7th Edition)

Cummings, J., et al. (2024). Dextromethorphan-bupropion for agitation in Alzheimer’s disease: Randomized controlled trial results. JAMA Neurology, 81(2), 1–10.

Grossberg, G. T., et al. (2023). Efficacy and safety of dextromethorphan-bupropion in Alzheimer’s agitation. Alzheimer’s & Dementia, 19(5), 1452–1463.

Olin, J. T., et al. (2023). Agitation in Alzheimer’s disease: Advances in pharmacologic management. CNS Drugs, 37(4), 345–360.

Wilkinson, D., et al. (2024). Emerging treatments for behavioral symptoms in dementia. Lancet Neurology, 23(1), 75–88.

Food and Drug Administration. (2025). FDA approval announcement for dextromethorphan-bupropion in agitation associated with Alzheimer’s disease.

Danielle Parks
Next

Chrono-Nutrition and Mental Health: How Meal Timing Impacts Sleep, Mood, and Brain Function in Reno, Nevada